Trials that use: Confidence intervals
New to this method? Read the tutorial →
407 results
- FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
- FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.
- FIRSTANAIndependent statistical analysis of the randomized phase 3 FIRSTANA trial of cabazitaxel versus docetaxel, both with prednisone, in patients with metastatic castration-resistant prostate cancer.
- FLAMEIndependent statistical analysis of the FLAME phase 3 trial of QVA149 versus LABA/ICS in COPD, including exacerbation rates, time-to-event analyses, non-inferiority methodology, safety, and statistical interpretation.
- FLAMINGOComplete statistical analysis of the FLAMINGO phase 3 trial comparing dolutegravir with darunavir/ritonavir, each combined with dual NRTIs in ART-naive participants with HIV-1 infection.
- FLAURAComplete statistical analysis of the phase 3 FLAURA trial of osimertinib versus standard-of-care EGFR-TKI therapy in locally advanced or metastatic EGFR sensitising mutation-positive non-small cell lung cancer.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…
- FOURIERIndependent statistical analysis of the FOURIER phase 3 trial of evolocumab versus placebo in subjects with elevated cardiovascular risk and dyslipidemia, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, and interpretation.
- FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…
- FREEDOM-CIndependent statistical analysis of FREEDOM-C, evaluating oral treprostinil versus placebo in pulmonary arterial hypertension, including trial design, 6MWD results, secondary endpoints, post-hoc analyses, statistical methodology, and interpretation.
- FREEDOM-C2Independent statistical analysis of the FREEDOM-C2 phase 3 trial of UT-15C SR versus placebo for pulmonary arterial hypertension, including the 6-minute walk distance endpoint, non-parametric ANCOVA, secondary analyses, safety, and statistical interpretation.
- FREEDOM-EVIndependent statistical analysis of FREEDOM-EV, a randomized phase 3 trial of treprostinil diolamine versus placebo in pulmonary arterial hypertension, covering clinical worsening, 6-minute walk distance, NT-proBNP, functional class, statistical methods, and safety.
- FREEDOM-MIndependent statistical analysis of FREEDOM-M, a randomized phase 3 trial of oral treprostinil versus placebo for pulmonary arterial hypertension, including 6-minute walk distance, statistical methodology, secondary analyses, safety, and interpretation.
- FRESCO-2Independent statistical analysis of the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care versus placebo plus best supportive care in metastatic colorectal cancer, including overall survival, progression-free survival, response, statistical…
- GADOLINIndependent statistical analysis of the phase 3 GADOLIN trial of obinutuzumab plus bendamustine versus bendamustine alone in participants with rituximab-refractory, indolent non-Hodgkin's lymphoma.
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- GALILEOComplete statistical analysis of the GALILEO phase 3 trial comparing a rivaroxaban-based antithrombotic strategy with an antiplatelet-based strategy after transcatheter aortic valve replacement, including endpoints, hazard ratios, confidence intervals, non-inferiority analysis, safety,…
- GEMINI-ACS-1Independent statistical analysis of GEMINI-ACS-1, a randomized phase 2 trial comparing rivaroxaban with acetylsalicylic acid in addition to P2Y12 inhibitor therapy in participants with acute coronary syndrome.
- GLOWIndependent statistical analysis of the phase 3 GLOW trial of zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, including time-to-event methodology, reported efficacy results,…
- GOG-0218Independent statistical analysis of GOG-0218, a randomized phase 3 trial of carboplatin and paclitaxel with or without bevacizumab in patients with stage III or stage IV ovarian, primary peritoneal, or fallopian tube…
- GOG-0252Independent statistical analysis of GOG-0252, a randomized phase 3 trial of bevacizumab with intravenous or intraperitoneal chemotherapy in patients with stage II-III ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- GOLDEN-3Independent statistical analysis of GOLDEN-3 (NCT02347761), a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its FEV1 endpoint, MMRM methodology, multiplicity control, confidence intervals, and reported results.
- GOLDEN-4Independent statistical analysis of GOLDEN-4, a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its MMRM methodology, primary FEV1 results, multiplicity approach, safety data, and statistical interpretation.
- GOYAIndependent statistical analysis of the GOYA phase 3 trial of obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in participants with CD20-positive diffuse large B-cell lymphoma, including trial design, progression-free survival, statistical methodology,…
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- GS-US-236-0102Independent statistical analysis of GS-US-236-0102, a randomized phase 3 trial comparing Stribild with Atripla in antiretroviral treatment-naive adults with HIV-1 infection, including the Week 48 virologic-success endpoint, non-inferiority framework, Wald/z-test methodology, and…
- GS-US-236-0103Independent statistical analysis of GS-US-236-0103 (NCT01106586), a randomized phase 3 study comparing Stribild with ritonavir-boosted atazanavir plus Truvada in antiretroviral treatment-naive adults with HIV-1.
- GS-US-292-0104Independent statistical analysis of GS-US-292-0104 (NCT01780506), a randomized phase 3 trial comparing E/C/F/TAF with E/C/F/TDF in antiretroviral treatment-naive adults with HIV-1 infection, including its non-inferiority analysis, risk difference, confidence interval, and Cochran-Mantel-Haenszel…
- GS-US-292-0109Independent statistical analysis of GS-US-292-0109 (NCT01815736), a randomized phase 3 trial evaluating switching from a TDF-containing regimen to E/C/F/TAF in virologically suppressed HIV-1-positive participants.
- HER2CLIMB-02Independent statistical analysis of HER2CLIMB-02, the randomized phase 3 trial of tucatinib with ado-trastuzumab emtansine in advanced or metastatic HER2-positive breast cancer, including time-to-event methodology, reported efficacy estimates, safety, and statistical interpretation.
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- Hokusai-VTEA complete statistical analysis of Hokusai-VTE, the randomized phase 3 trial comparing heparin/edoxaban with heparin/warfarin for symptomatic venous thromboembolism, including non-inferiority analysis, Cox modeling, bleeding outcomes, and statistical interpretation.
- HPTN 052Independent statistical analysis of HPTN 052, a randomized phase 3 trial evaluating early versus delayed antiretroviral therapy and linked and all partner HIV infection rates.
- HPTN 083Independent statistical analysis of HPTN 083, a randomized phase 2/3 trial comparing injectable cabotegravir with TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected men and transgender women who have sex with men.
- HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…
- HVTN 702Independent statistical analysis of HVTN 702, a randomized phase 2/3 HIV vaccine prevention trial evaluating ALVAC-HIV and bivalent subtype C gp120/MF59 versus placebo, including time-to-event methods, hazard ratios, confidence intervals, safety, and…
- IBCSG 23-01Independent statistical analysis of IBCSG 23-01, a randomized trial of axillary lymph node dissection versus no axillary lymph node dissection in women with node-negative breast cancer and sentinel lymph node micrometastases.
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- IMblaze370Independent statistical analysis of IMblaze370, a randomized phase 3 trial comparing cobimetinib plus atezolizumab and atezolizumab monotherapy with regorafenib in metastatic colorectal adenocarcinoma.
- IMbrave050Independent statistical analysis of IMbrave050, a randomized phase 3 trial of atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in hepatocellular carcinoma at high risk of recurrence after surgical resection or…
- IMpassion130Complete statistical analysis of IMpassion130, a randomized phase 3 trial of atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated metastatic triple-negative breast cancer.
- IMpassion131Independent statistical analysis of IMpassion131, a randomized phase 3 trial of atezolizumab plus paclitaxel versus placebo plus paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.
- IMpower010Independent statistical analysis of IMpower010, the randomized phase 3 trial of atezolizumab versus best supportive care following chemotherapy in non-small cell lung cancer, including disease-free survival, time-to-event methodology, confidence intervals, and interpretation.
- IMpower132Independent statistical analysis of IMpower132, a phase 3 randomized trial of atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in chemotherapy-naive participants with stage IV non-squamous non-small cell lung cancer.
- IMpower133Independent statistical analysis of IMpower133 (NCT02763579), a randomized phase 3 trial of atezolizumab plus carboplatin and etoposide versus placebo plus carboplatin and etoposide in untreated extensive-stage small cell lung cancer.
- IMvigor010Independent statistical analysis of IMvigor010, the randomized phase 3 study of atezolizumab versus observation as adjuvant therapy after surgical resection for high-risk muscle-invasive urothelial carcinoma.
- IMvigor130Independent statistical analysis of IMvigor130, a randomized phase 3 trial of atezolizumab with platinum-based chemotherapy or as monotherapy in untreated locally advanced or metastatic urothelial carcinoma.
- IMvigor211Independent statistical analysis of the phase 3 IMvigor211 trial of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer, including overall survival, hazard ratios, confidence intervals, and…
- INAVO120Independent statistical analysis of the INAVO120 trial of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.